Log in

NASDAQ:ALBOAlbireo Pharma Stock Price, Forecast & News

$26.76
-0.26 (-0.96 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$25.98
Now: $26.76
$27.57
50-Day Range
$16.40
MA: $22.26
$27.33
52-Week Range
$11.26
Now: $26.76
$35.76
Volume45,830 shs
Average Volume71,993 shs
Market Capitalization$400.86 million
P/E RatioN/A
Dividend YieldN/A
Beta1.89
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat, an orally administered IBAT inhibitor for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis; and A3384 for the treatment of bile acid malabsorption. It has a license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
Read More
Albireo Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.51 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALBO
CUSIPN/A
Phone857-254-5555

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.64 million
Book Value$7.57 per share

Profitability

Net Income$-62,720,000.00
Net Margins-730.55%

Miscellaneous

Employees39
Market Cap$400.86 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive ALBO News and Ratings via Email

Sign-up to receive the latest news and ratings for ALBO and its competitors with MarketBeat's FREE daily newsletter.

Albireo Pharma (NASDAQ:ALBO) Frequently Asked Questions

How has Albireo Pharma's stock been impacted by COVID-19 (Coronavirus)?

Albireo Pharma's stock was trading at $17.63 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ALBO shares have increased by 51.8% and is now trading at $26.76. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Albireo Pharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Albireo Pharma.

When is Albireo Pharma's next earnings date?

Albireo Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Albireo Pharma.

How were Albireo Pharma's earnings last quarter?

Albireo Pharma Inc (NASDAQ:ALBO) issued its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($2.23) earnings per share for the quarter, missing the consensus estimate of ($1.39) by $0.84. The biopharmaceutical company had revenue of $1.55 million for the quarter, compared to analysts' expectations of $1.19 million. Albireo Pharma had a negative return on equity of 72.82% and a negative net margin of 730.55%. View Albireo Pharma's earnings history.

What price target have analysts set for ALBO?

5 brokers have issued 1 year target prices for Albireo Pharma's shares. Their forecasts range from $39.00 to $62.00. On average, they anticipate Albireo Pharma's stock price to reach $52.75 in the next year. This suggests a possible upside of 97.1% from the stock's current price. View analysts' price targets for Albireo Pharma.

Has Albireo Pharma been receiving favorable news coverage?

Headlines about ALBO stock have trended very negative this week, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Albireo Pharma earned a media sentiment score of -3.7 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutAlbireo Pharma.

Who are some of Albireo Pharma's key competitors?

What other stocks do shareholders of Albireo Pharma own?

Who are Albireo Pharma's key executives?

Albireo Pharma's management team includes the following people:
  • Mr. Ronald H. W. Cooper, CEO, Pres & Director (Age 56)
  • Ms. Martha J. Carter, Chief Regulatory Officer (Age 67)
  • Dr. Paresh N. Soni, Consultant (Age 59)
  • Dr. Per-Goran Gillberg, Co-Founder & VP of Devel.
  • Mr. Simon Harford, CFO & Treasurer

What is Albireo Pharma's stock symbol?

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Who are Albireo Pharma's major shareholders?

Albireo Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (13.09%), Federated Hermes Inc. (12.77%), ArrowMark Colorado Holdings LLC (6.49%), BlackRock Inc. (5.13%), Chicago Capital LLC (3.30%) and Prosight Management LP (2.21%). Company insiders that own Albireo Pharma stock include Jan Mattsson, Pamela Stephenson, Patrick Taylor Horn, Perceptive Advisors Llc, Ronald Harold Wilfred Cooper and Simon NR Harford. View institutional ownership trends for Albireo Pharma.

Which institutional investors are selling Albireo Pharma stock?

ALBO stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Two Sigma Investments LP, Wells Fargo & Company MN, Victory Capital Management Inc., Victory Capital Management Inc., Parametric Portfolio Associates LLC, and MAI Capital Management. Company insiders that have sold Albireo Pharma company stock in the last year include Pamela Stephenson, Patrick Taylor Horn, and Simon NR Harford. View insider buying and selling activity for Albireo Pharma.

Which institutional investors are buying Albireo Pharma stock?

ALBO stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Chicago Capital LLC, Perceptive Advisors LLC, ArrowMark Colorado Holdings LLC, Prosight Management LP, BlackRock Inc., Deutsche Bank AG, and Geode Capital Management LLC. Company insiders that have bought Albireo Pharma stock in the last two years include Perceptive Advisors Llc, and Ronald Harold Wilfred Cooper. View insider buying and selling activity for Albireo Pharma.

How do I buy shares of Albireo Pharma?

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Albireo Pharma's stock price today?

One share of ALBO stock can currently be purchased for approximately $26.76.

How big of a company is Albireo Pharma?

Albireo Pharma has a market capitalization of $400.86 million and generates $9.64 million in revenue each year. The biopharmaceutical company earns $-62,720,000.00 in net income (profit) each year or ($5.04) on an earnings per share basis. Albireo Pharma employs 39 workers across the globe.

What is Albireo Pharma's official website?

The official website for Albireo Pharma is www.albireopharma.com.

How can I contact Albireo Pharma?

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at 857-254-5555 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.